non-hodgkin`s lymphoma	is a	cancer
non-hodgkin`s lymphoma	is a	hematologic malignancy
non-hodgkin`s lymphoma	has subtypes	diffuse large B-cell lymphoma
non-hodgkin`s lymphoma	has subtypes	follicular lymphoma
non-hodgkin`s lymphoma	has subtypes	mantle cell lymphoma
non-hodgkin`s lymphoma	has subtypes	marginal zone lymphoma
non-hodgkin`s lymphoma	has subtypes	Burkitt lymphoma
non-hodgkin`s lymphoma	has subtypes	small lymphocytic lymphoma
non-hodgkin`s lymphoma	has subtypes	peripheral T-cell lymphoma
non-hodgkin`s lymphoma	is associated with	immunosuppression
non-hodgkin`s lymphoma	is associated with	HIV infection
non-hodgkin`s lymphoma	is associated with	autoimmune disease
non-hodgkin`s lymphoma	is associated with	Epstein-Barr virus
non-hodgkin`s lymphoma	is associated with	hepatitis C virus
non-hodgkin`s lymphoma	is diagnosed by	tissue biopsy
non-hodgkin`s lymphoma	is diagnosed by	immunophenotyping
non-hodgkin`s lymphoma	is diagnosed by	flow cytometry
non-hodgkin`s lymphoma	is diagnosed by	PET-CT
non-hodgkin`s lymphoma	presents with	lymphadenopathy
non-hodgkin`s lymphoma	presents with	fever
non-hodgkin`s lymphoma	presents with	night sweats
non-hodgkin`s lymphoma	presents with	weight loss
stage	influences	treatment decisions
stage	determines	prognosis
IPI score	stratifies	risk group
beta-2 microglobulin	is a	prognostic marker
LDH	is a	prognostic marker
survival	depends on	stage
autologous stem cell transplant	is a	treatment option
chemotherapy	is a	treatment option
radiation therapy	is a	treatment option
R-CHOP regimen	is a	standard therapy
R-EPOCH regimen	is a	alternative therapy
bendamustine	is a	chemotherapy agent
rituximab	is a	monoclonal antibody
ibrutinib	is a	targeted therapy
carboplatin	is a	chemotherapy agent
tissue biopsy	confirms	non-hodgkin`s lymphoma
immunohistochemistry	shows	CD20 expression
flow cytometry	shows	CD19 expression
imaging	used for	staging
bone marrow biopsy	assesses	bone marrow involvement
bone marrow involvement	worsens	prognosis
B symptoms	indicate	systemic disease
HIV infection	increases	NHL risk
immunosuppression	increases	NHL risk
autoimmune disease	increases	NHL risk
Epstein-Barr virus	associated with	Burkitt lymphoma
EBV infection	linked to	NHL subtypes
pediatric patient	presents with	NHL
pediatric NHL	occurs in	children
chemotherapy toxicity	leads to	cytopenias
cytopenias	cause	infection risk
neutropenia	increases	infection risk
tumor lysis syndrome	occurs with	high tumor burden
high tumor burden	predicts	poor prognosis
PET-CT	assesses	metabolic activity
complete response	indicates	remission
partial response	indicates	response to therapy
relapse	occurs after	initial response
progression	indicates	therapy failure
central nervous system involvement	indicates	advanced disease
Ann Arbor staging	defines	disease extent
staging	uses	Ann Arbor system
prognosis	varies by	subtype
diffuse large B-cell lymphoma	is a	aggressive subtype
follicular lymphoma	is a	indolent lymphoma
mantle cell lymphoma	is a	aggressive lymphoma
marginal zone lymphoma	is a	indolent lymphoma
Burkitt lymphoma	is a	highly aggressive lymphoma
small lymphocytic lymphoma	is a	low-grade lymphoma
peripheral T-cell lymphoma	is a	rare NHL subtype
rituximab	targets	CD20 antigen
CD20 antigen	expressed on	B-cell lymphomas
B-cell lymphomas	express	CD20 antigen
progression-free survival	is an	endpoint
overall survival	is an	endpoint
PET-CT	used for	response assessment
immunochemotherapy	is a	combination therapy
autologous transplant	improves	progression-free survival
clinical trial	investigates	new therapies
new therapy	shows	efficacy
therapy response	measured by	imaging
imaging response	correlates with	survival
cytogenetic abnormality	predicts	prognosis
t(14;18) translocation	found in	follicular lymphoma
MYC translocation	associated with	Burkitt lymphoma
BCL2 rearrangement	associated with	follicular lymphoma
CD10 expression	observed in	follicular lymphoma
beta-2 microglobulin	elevated in	NHL
intrathecal chemotherapy	used for	CNS prophylaxis
CNS prophylaxis	used in	high-risk NHL
relapse risk	depends on	subtype
age	impacts	treatment tolerance
comorbidity	affects	treatment choice
nutritional status	affects	immune function
infection risk	increases	hospitalization
hospitalization	associated with	chemotherapy toxicity
healthcare cost	increases	management of NHL
quality of life	impacts	patient well-being
